MPM Oncology Impact Management as of March 31, 2021
Portfolio Holdings for MPM Oncology Impact Management
MPM Oncology Impact Management holds 13 positions in its portfolio as reported in the March 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Cullinan Management Common (CGEM) | 41.4 | $330M | 7.9M | 41.67 | |
| Harpoon Therapeutics Common | 10.2 | $82M | 3.9M | 20.92 | |
| iTeos Therapeutics Common (ITOS) | 10.1 | $81M | 2.4M | 34.18 | |
| TCR2 Therapeutics Common | 9.4 | $74M | 3.4M | 22.08 | |
| Repare Therapeutics Common (RPTX) | 8.0 | $64M | 2.1M | 30.69 | |
| MEI Pharma Common | 4.4 | $35M | 10M | 3.43 | |
| Oncorus Common | 4.2 | $33M | 2.4M | 13.92 | |
| Turning Point Therapeutics Common | 3.2 | $26M | 269k | 94.59 | |
| G1 Therapeutics Common (GTHX) | 2.8 | $22M | 928k | 24.06 | |
| Epizyme Common | 2.6 | $20M | 2.3M | 8.71 | |
| Merus Common (MRUS) | 1.8 | $15M | 701k | 20.89 | |
| YmAbs Therapeutics Common (YMAB) | 1.3 | $10M | 337k | 30.24 | |
| ADC Therapeutics Common (ADCT) | 0.7 | $5.3M | 218k | 24.41 |
